WALTHAM, Mass. — BostonGene has published a landmark study confirming the clinical and analytical validation of its Tumor Portrait™ assay, a combined RNA and DNA exome sequencing platform designed to advance precision oncology and improve patient stratification in drug development. The findings appeared in Communications Medicine, a journal in the Nature portfolio.
The Tumor Portrait™ assay integrates DNA and RNA sequencing into a single, regulatory-grade test, providing a multimodal view of tumors. Approved under CLIA, CAP, and the New York State Department of Health, the platform supports biomarker discovery, clinical trial enrollment, and patient selection, all aimed at reducing drug development risks and improving trial success rates.
Tested on more than 2,200 tumors, the assay demonstrated high reproducibility, identified clinically actionable insights in 98% of cases, and detected genetic alterations, fusions, immune signatures, and tumor microenvironment profiles. The system also incorporates AI-based predictive classifications to guide oncology research and treatment strategies.
“Delivering clinically validated multimodal data from a single tumor sample—and interpreting it through an immune-focused, AI-enabled lens—represents a transformative advancement for oncology drug development,” said Alexander Bagaev, PhD, BostonGene’s chief product officer. “By combining DNA and RNA sequencing in one assay, our platform enables deeper biological understanding, smarter patient selection, and more confident, data-driven decisions throughout the drug development lifecycle.”
BostonGene said the validation underscores the platform’s role as the foundation of its AI-powered solutions for therapeutic development and clinical data collection in oncology.
